Opportunity ID: 264192

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: RFA-CA-14-018
Funding Opportunity Title:: Pediatric Preclinical Testing Consortium: Research Programs (U01)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Education
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s):: 93.395 — Cancer Treatment Research
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 2
Posted Date:: Sep 05, 2014
Last Updated Date:: Sep 05, 2014
Original Closing Date for Applications:: Nov 13, 2014
Current Closing Date for Applications:: Nov 13, 2014
Archive Date:: Dec 14, 2014
Estimated Total Program Funding::
Award Ceiling:: $
Award Floor:: $

Eligibility

Eligible Applicants:: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name:: National Institutes of Health
Description:: This Funding Opportunity Announcement (FOA) is for Research Programs for in vivo and in vitro testing of the activity of pediatric anticancer drug candidates. These Research Programs are the fundamental part of the Pediatric Preclinical Testing Consortium (PPTC) initiative, which also includes a PPTC Coordinating Center (supported under RFA-CA-14-019). The main goal for PPTC is to develop a rigorous preclinical testing system for pediatric anticancer drug candidates and to generate reliable data that can be used to inform new agent prioritization decisions. This FOA invites applications for drug testing Research Programs focused on specific tumor types that are particularly relevant to pediatric oncology. Each application must propose only one testing Research Program from the following four types:Type A: Research Program for leukemia in vivo testing;Type B: Research Program for tumors of central nervous system (CNS) in vivo testing; Type C: Research Program for other (non-CNS) solid tumors testing in vivo; and Type D: Research Program for in vitro testing.Applicants may propose Research Programs of more than one type but only through separate applications for each. Applicants proposing in vivo testing programs must be capable of quantitative assessment of tumor regression and time to event for 6 to 10 new agents (or combinations of agents) annually across relevant, well-characterized preclinical models. All applicants are expected to have substantial expertise regarding the biology and therapeutic opportunities for the tumor types that they propose to study. The PPTC Research Program Awardees will be required to collaborate closely with the PPTC Coordinating Center.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version Modification Description Updated Date
Synopsis 2 Corrected Eligible Applicants field Sep 05, 2014
Synopsis 1

Package Status

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Packages

Assistance Listings Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions Who Can Apply:
FORMS-C FORMS-C PKG00205224 Oct 13, 2014 Nov 13, 2014 View eRA Commons Help Desk Organization Applicants